Full Press Release Details
INDIANAPOLIS , July 20, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that new results from a number of studies across the company's Alzheimer's disease pipeline will be presented at the Alzheimer's Association International Conference (AAIC) in Chicago , July 22-26, 2018 . Nearly 30 oral and poster presentations will underscore Lilly's focus on making a meaningful difference in the lives of people living with Alzheimer's through clinical development and collaboration.
"Lilly's commitment to Alzheimer's research continues," said Phyllis Ferrell , vice president, Global Alzheimer's Disease Platform Team. "The research findings we are sharing at this year's meeting highlight our ongoing efforts to find solutions that may lead to a disease-modifying therapy. The patients and their loved ones we aim to help can't quit, and neither will we."
Studies being presented about Lilly molecules include (please note, all times listed below are Central Daylight Time):
Alzheimer's Disease Care Environment
N3pG mAb and BACE Inhibitor Combination
Selective BACE 1 Inhibitor
Biomarkers in Alzheimer's Disease
Flortaucipir PET Tracer
About Alzheimer's Disease
Alzheimer's disease is a fatal illness that causes progressive decline in memory and other aspects of cognition. 1 Dementia due to Alzheimer's disease is the most common form of dementia, accounting for 60 to 80 percent of all cases. 2 There are currently an estimated 50 million people living with dementia around the world, with numbers expected to increase to nearly 75 million by 2030 and 132 million by 2050. Almost 10 million new cases of dementia are diagnosed each year worldwide, implying one new case approximately every 3 seconds. The current total annual societal and economic estimated cost of dementia is $818 billion USD worldwide and this year may rise above a trillion USD. 3
About Eli Lilly and Company Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and www.lilly.com/newsroom/social-channels . P-LLY
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about investigational treatments and diagnostics for Alzheimer's disease and reflects Lilly's current belief. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that future study results will be consistent with the results to date or that these investigational compounds or diagnostics will achieve primary study endpoints or receive regulatory approvals. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
1 Alzheimer's Association. What is Alzheimer's? http://www.alz.org/alzheimers_disease_what_is_alzheimers.asp . Accessed April 2018. 2 Alzheimer's Association. What is Dementia? http://www.alz.org/what-is-dementia.asp . Accessed April 2018. 3 Alzheimer's Disease International. Dementia Statistics. https://www.alz.co.uk/research/statistics . Accessed April 2018 .
| Refer to: | Nicole Hebert; [email protected] ; 317-701-9984 (media) |
| Kevin Hern; [email protected] ; 317-277-1838 (investors) |
SOURCE Eli Lilly and Company